AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer

11 hours ago 2

• Healthcare

• Comments

koto_feja

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have received priority review from the FDA for their supplemental marketing application for Enhertu in combination with pertuzumab, marketed by Roche (OTCQX:RHHBY) as Perjeta.

This application is aimed at treating adults with HER2-positive breast cancer

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer